Compare ARL & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARL | DCTH |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 289.2M |
| IPO Year | N/A | N/A |
| Metric | ARL | DCTH |
|---|---|---|
| Price | $16.10 | $9.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $22.60 |
| AVG Volume (30 Days) | 1.6K | ★ 748.8K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | 0.03 |
| Revenue | $49,060,000.00 | ★ $79,603,000.00 |
| Revenue This Year | N/A | $131.97 |
| Revenue Next Year | N/A | $38.84 |
| P/E Ratio | ★ $42.90 | $300.53 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $9.43 | $8.12 |
| 52 Week High | $17.00 | $18.23 |
| Indicator | ARL | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 56.07 |
| Support Level | $15.26 | $9.59 |
| Resistance Level | $15.98 | $10.65 |
| Average True Range (ATR) | 0.22 | 0.45 |
| MACD | 0.05 | 0.13 |
| Stochastic Oscillator | 65.71 | 63.00 |
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.